The main aim of this study is to assess efficacy of metronomic chemotherapy, in terms of disease control after two cycles of metronomic chemotherapy .~Other objectives of the study include:~To evaluate disease control obtained with metronomic chemotherapy, in terms of progression-free survival (PFS) and overall survival (OS).~Evaluating early response after one cycle of treatment of metronomic treatment;~Evaluating best tumor response over the whole metronomic treatment duration;~Evaluating safety of the proposed metronomic chemotherapy;~Evaluating the feasibility of the proposed metronomic chemotherapy.~To evaluate quality of life using Kindl® Quality of Life questionnaire at baseline (before start of treatment), and approximately at weeks 7 and 13 of treatment
This is a multicenter, interventional, non-randomized study among patients with a relapsed or refractory Wilms tumor. The study will aim to assess efficacy of metronomic chemotherapy, in terms of disease control after two cycles of metronomic chemotherapy.